LadRx (OTCMKTS:CYTR) versus MeiraGTx (NASDAQ:MGTX) Financial Contrast

LadRx (OTCMKTS:CYTR) and MeiraGTx (NASDAQ:MGTX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk and analyst recommendations.

Profitability

This table compares LadRx and MeiraGTx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
LadRx	N/A	-67.61%	-45.39%
MeiraGTx	-1,146.81%	-152.82%	-56.41%

Valuation & Earnings

This table compares LadRx and MeiraGTx”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LadRx	N/A	N/A	-$6.70 million	($0.15)	N/A
MeiraGTx	$8.12 million	34.52	-$84.03 million	($1.17)	-3.73

LadRx has higher earnings, but lower revenue than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than LadRx, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

0.1% of LadRx shares are owned by institutional investors. Comparatively, 67.5% of MeiraGTx shares are owned by institutional investors. 12.8% of LadRx shares are owned by company insiders. Comparatively, 8.4% of MeiraGTx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

LadRx has a beta of 1.96, meaning that its share price is 96% more volatile than the S&P 500. Comparatively, MeiraGTx has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for LadRx and MeiraGTx, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LadRx	0	0	0	0	N/A
MeiraGTx	0	0	2	0	3.00

MeiraGTx has a consensus price target of $22.50, indicating a potential upside of 416.06%.

Summary

LadRx beats MeiraGTx on 8 of the 11 factors compared between the two stocks.

About LadRx

LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.

About MeiraGTx

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.